{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:06:58Z","timestamp":1770912418981,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jpba.2024.116108","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T05:17:09Z","timestamp":1710566229000},"page":"116108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A multiplex UPLC-MS\/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum"],"prefix":"10.1016","volume":"243","author":[{"given":"Pauline L.M.","family":"Buitelaar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A.M.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Aardenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116108_bib1","unstructured":"European Medicines Agency. EPAR - Bavencio. [Internet]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bavencio\u3009. [Accessed April 20 2023]."},{"key":"10.1016\/j.jpba.2024.116108_bib2","unstructured":"European Medicines Agency. EPAR - Imfinzi. [Internet]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imfinzi\u3009. [Accessed April 20 2023]."},{"key":"10.1016\/j.jpba.2024.116108_bib3","unstructured":"European Medicines Agency. EPAR - Tecentriq. [Internet]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecentriq\u3009. [Accessed April 20 2023]."},{"key":"10.1016\/j.jpba.2024.116108_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharm."},{"key":"10.1016\/j.jpba.2024.116108_bib5","unstructured":"European Medicines Agency. Assessment report - Tecentriq. [Internet]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/tecentriq-epar-public-assessment-report_en.pdf\u3009. [Accessed July 25 2023]."},{"key":"10.1016\/j.jpba.2024.116108_bib6","unstructured":"U.S. Food and Drug Administration. BLA Multidisciplinary Review and Evaluation: BLA 761049 Bavencio (Avelumab). [Internet]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761049orig1s000multidiscipliner.pdf\u3009. [Accessed July 25 2023]."},{"key":"10.1016\/j.jpba.2024.116108_bib7","unstructured":"U.S. Food and Drug Administration. BLA Multidisciplinary Review and Evaluation: BLA 761069 Imfinzi (Durvalumab). [Internet]. Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761069Orig1s000ClinPharmR.pdf\u3009. [Accessed July 25 2023]."},{"issue":"7","key":"10.1016\/j.jpba.2024.116108_bib8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin. Pharm."},{"issue":"8","key":"10.1016\/j.jpba.2024.116108_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4155\/bio.16.24","article-title":"Techniques for quantitative LC-MS\/MS analysis of protein therapeutics: advances in enzyme digestion and immunocapture","volume":"8","author":"Fung","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2024.116108_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchromb.2011.09.030","article-title":"LC-MS\/MS for protein and peptide quantification in clinical chemistry","volume":"883-884","author":"Rauh","year":"2012","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"4","key":"10.1016\/j.jpba.2024.116108_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4155\/bio-2019-0279","article-title":"IQ consortium perspective: complementary LBA and LC-MS in protein therapeutics bioanalysis and biotransformation assessment","volume":"12","author":"Kaur","year":"2020","journal-title":"Bioanalysis"},{"issue":"6","key":"10.1016\/j.jpba.2024.116108_bib12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/FTD.0000000000000558","article-title":"An LC-MS\/MS method for absolute quantification of nivolumab in human plasma: application to clinical therapeutic drug monitoring","volume":"40","author":"Irie","year":"2018","journal-title":"Ther. Drug Monit."},{"issue":"8","key":"10.1016\/j.jpba.2024.116108_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ph14080796","article-title":"Cross-validation of a multiplex LC-MS\/MS method for assaying mAbs plasma levels in patients with cancer: a GPCO-UNICANCER study","volume":"14","author":"Marin","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jpba.2024.116108_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114515","article-title":"Development and validation of a UPLC-MS\/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay","volume":"209","author":"Liu","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116108_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123215","article-title":"Optimized sample pre-treatment procedure for the simultaneous UPLC-MS\/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum","volume":"1196","author":"de Jong","year":"2022","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2024.116108_bib16","unstructured":"National Library of Medicine. National Center for Biotechnology Information - Standard Protein BLAST [Internet]. 2023. Available from: \u3008https:\/\/blast.ncbi.nlm.nih.gov\/Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome\u3009. [Accessed March 20 2020]."},{"key":"10.1016\/j.jpba.2024.116108_bib17","unstructured":"European Medicines Agency. ICH guideline M10 on bioanalytical method validation and study sample analysis. [Internet]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf\u3009. [Accessed April 24 2023]."},{"issue":"1","key":"10.1016\/j.jpba.2024.116108_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-014-9685-5","article-title":"Recommendations for validation of LC-MS\/MS bioanalytical methods for protein biotherapeutics","volume":"17","author":"Jenkins","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2024.116108_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02894","article-title":"Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (The PERICLES Study): a phase II Trial","author":"de Vries","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2024.116108_bib20","unstructured":"NIH National Library of Medicines ClinicalTrials.gov. PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study (PERICLES). [Internet]. Available from: \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT03686332\u3009. [Accessed November 5 2023]."},{"issue":"6","key":"10.1016\/j.jpba.2024.116108_bib21","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/foods11060880","article-title":"Effects of ultrasonic treatment on the structure, functional properties of chickpea protein isolate and its digestibility in vitro","volume":"11","author":"Kang","year":"2022","journal-title":"Foods"},{"key":"10.1016\/j.jpba.2024.116108_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ultsonch.2022.106010","article-title":"Ultrasonication as an innovative approach to tailor the apple seed proteins into nanosize: effect on protein structural and functional properties","volume":"86","author":"Gani","year":"2022","journal-title":"Ultrason. Sonochem."},{"issue":"10","key":"10.1016\/j.jpba.2024.116108_bib23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nmeth.2610","article-title":"DMSO enhances electrospray response, boosting sensitivity of proteomic experiments","volume":"10","author":"Hahne","year":"2013","journal-title":"Nat. Methods"},{"issue":"8","key":"10.1016\/j.jpba.2024.116108_bib24","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s13361-012-0404-0","article-title":"Charge state coalescence during electrospray ionization improves peptide identification by tandem mass spectrometry","volume":"23","author":"Meyer","year":"2012","journal-title":"J. Am. Soc. Mass Spectrom."},{"issue":"8","key":"10.1016\/j.jpba.2024.116108_bib25","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s13361-017-1670-7","article-title":"DMSO assisted electrospray ionization for the detection of small peptide hormones in urine by dilute-and-shoot-liquid-chromatography-high resolution mass spectrometry","volume":"28","author":"Jud\u00e1k","year":"2017","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.jpba.2024.116108_bib26","unstructured":"Food and Agriculture Organization of the United Nations. Annex 4 - Amino acids, on and three letter codes. [Internet]. Available from: \u3008https:\/\/www.fao.org\/3\/Y2775E\/y2775e0e.htm\u3009. [Accessed November 15 2023]."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T20:05:22Z","timestamp":1715285122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524001481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":26,"alternative-id":["S0731708524001481"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116108","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multiplex UPLC-MS\/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116108"}}